• Estrella Immunopharma filed a Form 12b-25 to delay its quarterly report on Form 10-Q for the period ended March 31, 2026.
• The filing cited an administrative delay in completing the filing process.
• The company expects to file the Form 10-Q on or before the fifth calendar day following the original due date.
• It did not expect a significant change in results of operations versus the prior-year period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-058062), on May 18, 2026, and is solely responsible for the information contained therein.